146 related articles for article (PubMed ID: 31245461)
1. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():70-80. PubMed ID: 31245461
[TBL] [Abstract][Full Text] [Related]
2. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():57-69. PubMed ID: 31245460
[TBL] [Abstract][Full Text] [Related]
3. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogeneic human induced pluripotent stem(-Like) cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():95-108. PubMed ID: 31245463
[TBL] [Abstract][Full Text] [Related]
4. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():81-94. PubMed ID: 31245462
[TBL] [Abstract][Full Text] [Related]
5. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():109-122. PubMed ID: 31245464
[TBL] [Abstract][Full Text] [Related]
6. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
Azuma K; Yamanaka S
Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
[TBL] [Abstract][Full Text] [Related]
7. [Regulatory science research to facilitate the development of cell/tissue-processed products].
Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
Okada K; Koike K; Sawa Y
Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
[TBL] [Abstract][Full Text] [Related]
10. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
11. Regenerative therapy by fusion of medicine and engineering: First-in-human clinical trials with induced pluripotent stem cells and cell sheet technology: A report of the Symposium of Regenerative Medicine for Patients.
Okano T; Sawa Y; Barber E; Umezawa A
Regen Ther; 2015 Dec; 2():2-5. PubMed ID: 31245453
[TBL] [Abstract][Full Text] [Related]
12. Tumorigenicity assessment of human cell-processed therapeutic products.
Yasuda S; Sato Y
Biologicals; 2015 Sep; 43(5):416-21. PubMed ID: 26071041
[TBL] [Abstract][Full Text] [Related]
13. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
[TBL] [Abstract][Full Text] [Related]
14. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
15. New Governmental Regulatory System for Stem Cell-Based Therapies in Japan.
Hara A; Sato D; Sahara Y
Ther Innov Regul Sci; 2014 Nov; 48(6):681-688. PubMed ID: 30227468
[TBL] [Abstract][Full Text] [Related]
16. A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell-derived allogeneic cell therapies.
Dashnau JL; Xue Q; Nelson M; Law E; Cao L; Hei D
Cytotherapy; 2023 Jan; 25(1):1-13. PubMed ID: 36109321
[TBL] [Abstract][Full Text] [Related]
17. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
18. Overview: Core technical elements for early product development, evaluation, and control of human cell-based products.
Hayakawa T
Biologicals; 2015 Sep; 43(5):410-5. PubMed ID: 26272542
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Toxicity Studies for Regenerative Medicine in Japan.
Shigeto J; Ichiki T; Nii T; Konno K; Nakanishi Y; Sugiyama D
Clin Ther; 2018 Nov; 40(11):1813-1822. PubMed ID: 30458928
[TBL] [Abstract][Full Text] [Related]
20. Basic points to consider regarding the preparation of extracellular vesicles and their clinical applications in Japan.
Tsuchiya A; Terai S; Horiguchi I; Homma Y; Saito A; Nakamura N; Sato Y; Ochiya T; Kino-Oka M;
Regen Ther; 2022 Dec; 21():19-24. PubMed ID: 35619946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
